Idexx Laboratories (IDXX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Sales | 2,706,655 | 2,406,908 | 2,213,242 | 1,969,058 | 1,775,423 |
| Cost of Goods | 1,135,615 | 1,041,359 | 971,700 | 871,676 | 799,987 |
| Gross Profit | 1,571,040 | 1,365,549 | 1,241,542 | 1,097,382 | 975,436 |
| Operating Expenses | 877,131 | 813,062 | 750,907 | 685,030 | 626,184 |
| Operating Income | 694,524 | 552,846 | 491,335 | 413,028 | 350,239 |
| Interest Expense | 33,125 | 31,055 | 34,744 | 37,225 | 32,049 |
| Other Income | 586 | 427 | 1,151 | 5,254 | 3,656 |
| Pre-tax Income | 661,985 | 522,218 | 457,742 | 381,057 | 321,846 |
| Income Tax | 79,854 | 94,426 | 80,695 | 117,788 | 99,792 |
| Net Income Continuous | 582,131 | 427,792 | 377,047 | 263,269 | 222,054 |
| Minority Interests | 355 | 72 | 16 | 125 | 9 |
| Net Income | $581,776 | $427,720 | $377,031 | $263,144 | $222,045 |
| EPS Basic Total Ops | 6.82 | 4.97 | 4.34 | 3.00 | 2.47 |
| EPS Basic Continuous Ops | 6.82 | 4.97 | 4.34 | 3.00 | 2.47 |
| EPS Diluted Total Ops | 6.71 | 4.89 | 4.26 | 2.94 | 2.44 |
| EPS Diluted Continuous Ops | 6.71 | 4.89 | 4.26 | 2.94 | 2.44 |
| EPS Diluted Before Non-Recurring Items | 6.71 | N/A | N/A | N/A | N/A |
| EBITDA(a) | $790,522 | $640,857 | $574,513 | $496,168 | $429,300 |